BiotechTube
Adze Biotechnology

Adze Biotechnology

San Francisco, United States· Est.
adzebiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Adze Biotechnology is a private, clinical-stage company leveraging a novel oncolytic viral backbone to create targeted immunotherapies. Its lead candidate, ADZE1.C, is in Phase 1 for metastatic melanoma, with a platform capable of systemic delivery and payload-carrying to enhance checkpoint inhibitor efficacy. Founded in 2019 and based in San Francisco, the company has raised a Series A and is advancing a pipeline focused on overcoming key limitations in current cancer immunotherapy.

Oncology

Technology Platform

Proprietary oncolytic viral backbone engineered for systemic delivery, tumor-specific targeting, conditional replication, and delivery of immune-modulating payloads (e.g., checkpoint inhibitors, cytokines) to reprogram the tumor microenvironment.

Opportunities

The large and growing checkpoint inhibitor market, where many patients are non-responders with 'cold' tumors, presents a major addressable opportunity for combination or standalone therapy.
The platform's systemic delivery capability could expand the reach of oncolytic virotherapy to metastatic and inaccessible tumors, a significant clinical and commercial advantage.

Risk Factors

High clinical development risk inherent to novel biologic platforms, including potential safety issues with systemically delivered replicating viruses and uncertain efficacy.
The company faces intense competition in immuno-oncology and is dependent on raising additional capital to fund operations beyond its Series A round.

Competitive Landscape

Adze competes in the oncolytic virotherapy segment with approved drugs like Amgen's T-VEC (intratumoral) and numerous clinical-stage companies (e.g., Replimune, Turnstone Bio). Its key differentiator is systemic delivery. It also competes broadly with other immuno-oncology modalities (bispecifics, cell therapies, next-gen CPIs) aiming to treat cold tumors.

More companies in Cell & Gene Therapy →More companies in United States →